Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 103 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Recombinant Interferon Gamma Clear all
Completed Phase 1 Interventional

Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer

NCT00004032
View directory record Official record
Conditions
Recurrent Ovarian Epithelial Cancer
Interventions
ALVAC-hB7.1, recombinant interferon gamma, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 9, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Gamma Interferon Therapy for Chronic Hepatitis C

NCT00028275
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Gamma Interferon 1b
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 6:53 PM EDT
Completed No phase listed Observational

The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis

NCT05235711
View directory record Official record
Conditions
Fungal Infection, Candidiasis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 9, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

NCT03063632
View directory record Official record
Conditions
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
Interventions
Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 9, 2026, 6:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

NCT02338973
View directory record Official record
Conditions
Inherited Ophthalmic Diseases, Inherited Retinal Degeneration
Interventions
Interferon gamma-1b
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 9, 2026, 6:53 PM EDT
Terminated Early Phase 1 Interventional Results available

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

NCT01957709
View directory record Official record
Conditions
Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
Interventions
Laboratory Biomarker Analysis, Recombinant Interferon Gamma
Other · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 9, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections

NCT00059878
View directory record Official record
Conditions
Infection, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant interferon gamma, voriconazole
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Little Rock, Arkansas • Gainesville, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 9, 2026, 6:53 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections

NCT04722029
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Adenovirus Specific T lymphocytes
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 9, 2026, 6:53 PM EDT
Completed Not applicable Interventional

The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS

NCT00002433
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon gamma-1b
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 6:53 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study of Emapalumab for Pediatric Aplastic Anemia

NCT06430788
View directory record Official record
Conditions
Aplastic Anemia, Cytopenia, Hypocellular Marrow
Interventions
Emapalumab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
0 Years to 25 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
6
States / cities
New York, New York • Cincinnati, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 9, 2026, 6:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Interferon Gamma for Macular Edema Secondary to Uveitis

NCT01376362
View directory record Official record
Conditions
Anterior Uveitis, Uveitis
Interventions
Interferon Gamma-1b
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Sep 9, 2026, 6:53 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer

NCT00047632
View directory record Official record
Conditions
Ovarian Carcinoma, Peritoneal Carcinoma
Interventions
Interferon gamma-1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
Female only
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Sep 9, 2026, 6:53 PM EDT
Completed No phase listed Observational

PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia

NCT04926922
View directory record Official record
Conditions
Tuberculosis, HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 9, 2026, 6:53 PM EDT
Completed Phase 3 Interventional

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

NCT00003414
View directory record Official record
Conditions
Graft Versus Host Disease, Lymphoma
Interventions
aldesleukin, recombinant interferon gamma, busulfan, cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2015 · Synced Sep 9, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

NCT04979052
View directory record Official record
Conditions
Candidemia
Interventions
Interferon Gamma-1B
Drug
Lead sponsor
Radboud University Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 9, 2026, 6:53 PM EDT
Completed Phase 1 Interventional

A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis

NCT00563212
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
aerosol interferon-gamma
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Sep 9, 2026, 6:53 PM EDT
Completed Phase 4 Interventional

A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood

NCT00001317
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
interferon-gamma
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 6:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

NCT03747484
View directory record Official record
Conditions
Other Skin
Interventions
Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Avelumab, Pembrolizumab, Interferon Gamma-1b
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 9, 2026, 6:53 PM EDT
Completed No phase listed Observational Results available

Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis

NCT06047210
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytoses
Interventions
Blood Draws Data Collection
Other
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 9, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

NCT00201123
View directory record Official record
Conditions
Tuberculosis, AIDS-related Complex
Interventions
Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 9, 2026, 6:53 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

NCT03985423
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytoses
Interventions
Emapalumab-Lzsg
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 9, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

NCT03311854
View directory record Official record
Conditions
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
0 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 9, 2026, 6:53 PM EDT
Completed Phase 3 Interventional

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

NCT00001296
View directory record Official record
Conditions
Melanoma
Interventions
melphalan, tumor necrosis factor, interferon-gamma, hyperthermic isolated limb perfusion
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 6:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV

NCT04364178
View directory record Official record
Conditions
Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus
Interventions
Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, EBV Specific T-Lymphocytes
Biological
Lead sponsor
Jessie L. Alexander, MD
Other
Eligibility
1 Month to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 9, 2026, 6:53 PM EDT